{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:23:14Z","timestamp":1792041794573,"version":"4.4.0"},"reference-count":289,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&amp;D Program of China","award":["2021YFA0805200"],"award-info":[{"award-number":["2021YFA0805200"]}]},{"name":"National Key R&amp;D Program of China","award":["202007030008"],"award-info":[{"award-number":["202007030008"]}]},{"name":"National Key R&amp;D Program of China","award":["202007030003"],"award-info":[{"award-number":["202007030003"]}]},{"name":"National Key R&amp;D Program of China","award":["82271902"],"award-info":[{"award-number":["82271902"]}]},{"name":"National Key R&amp;D Program of China","award":["82071421"],"award-info":[{"award-number":["82071421"]}]},{"name":"National Key R&amp;D Program of China","award":["82394422"],"award-info":[{"award-number":["82394422"]}]},{"name":"National Key R&amp;D Program of China","award":["82371874"],"award-info":[{"award-number":["82371874"]}]},{"name":"National Key R&amp;D Program of China","award":["81830032"],"award-info":[{"award-number":["81830032"]}]},{"name":"National Key R&amp;D Program of China","award":["31872779"],"award-info":[{"award-number":["31872779"]}]},{"name":"National Key R&amp;D Program of China","award":["81922026"],"award-info":[{"award-number":["81922026"]}]},{"name":"National Key R&amp;D Program of China","award":["82171244"],"award-info":[{"award-number":["82171244"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["2021YFA0805200"],"award-info":[{"award-number":["2021YFA0805200"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["202007030008"],"award-info":[{"award-number":["202007030008"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["202007030003"],"award-info":[{"award-number":["202007030003"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["82271902"],"award-info":[{"award-number":["82271902"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["82071421"],"award-info":[{"award-number":["82071421"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["82394422"],"award-info":[{"award-number":["82394422"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["82371874"],"award-info":[{"award-number":["82371874"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["81830032"],"award-info":[{"award-number":["81830032"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["31872779"],"award-info":[{"award-number":["31872779"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["81922026"],"award-info":[{"award-number":["81922026"]}]},{"name":"Guangzhou Key Research Program on Brain Science","award":["82171244"],"award-info":[{"award-number":["82171244"]}]},{"name":"National Science Foundation of China","award":["2021YFA0805200"],"award-info":[{"award-number":["2021YFA0805200"]}]},{"name":"National Science Foundation of China","award":["202007030008"],"award-info":[{"award-number":["202007030008"]}]},{"name":"National Science Foundation of China","award":["202007030003"],"award-info":[{"award-number":["202007030003"]}]},{"name":"National Science Foundation of China","award":["82271902"],"award-info":[{"award-number":["82271902"]}]},{"name":"National Science Foundation of China","award":["82071421"],"award-info":[{"award-number":["82071421"]}]},{"name":"National Science Foundation of China","award":["82394422"],"award-info":[{"award-number":["82394422"]}]},{"name":"National Science Foundation of China","award":["82371874"],"award-info":[{"award-number":["82371874"]}]},{"name":"National Science Foundation of China","award":["81830032"],"award-info":[{"award-number":["81830032"]}]},{"name":"National Science Foundation of China","award":["31872779"],"award-info":[{"award-number":["31872779"]}]},{"name":"National Science Foundation of China","award":["81922026"],"award-info":[{"award-number":["81922026"]}]},{"name":"National Science Foundation of China","award":["82171244"],"award-info":[{"award-number":["82171244"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Huntington\u2019s disease (HD) arises from the abnormal expansion of CAG repeats in the huntingtin gene (HTT), resulting in the production of the mutant huntingtin protein (mHTT) with a polyglutamine stretch in its N-terminus. The pathogenic mechanisms underlying HD are complex and not yet fully elucidated. However, mHTT forms aggregates and accumulates abnormally in neuronal nuclei and processes, leading to disruptions in multiple cellular functions. Although there is currently no effective curative treatment for HD, significant progress has been made in developing various therapeutic strategies to treat HD. In addition to drugs targeting the neuronal toxicity of mHTT, gene therapy approaches that aim to reduce the expression of the mutant HTT gene hold great promise for effective HD therapy. This review provides an overview of current HD treatments, discusses different therapeutic strategies, and aims to facilitate future therapeutic advancements in the field.<\/jats:p>","DOI":"10.3390\/ijms25073845","type":"journal-article","created":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T13:42:30Z","timestamp":1711892550000},"page":"3845","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Huntington\u2019s Disease: Complex Pathogenesis and Therapeutic Strategies"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-3128","authenticated-orcid":false,"given":"Huichun","family":"Tong","sequence":"first","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3112-9643","authenticated-orcid":false,"given":"Tianqi","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Xu","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongke","family":"Zhou","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurui","family":"Yin","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jiang","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-6536","authenticated-orcid":false,"given":"Shihua","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archneur.1993.00540110037003","article-title":"Molecular Genetics of Huntington\u2019s Disease","volume":"50","author":"Gusella","year":"1993","journal-title":"Arch. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s13311-012-0112-2","article-title":"Huntington\u2019s Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease","volume":"9","author":"Ehrlich","year":"2012","journal-title":"Neurotherapeutics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and Neuropathology of Huntington\u2019s Disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02257483","article-title":"Structure and expression of the Huntington\u2019s disease gene: Evidence against simple inactivation due to an expanded CAG repeat","volume":"20","author":"Ambrose","year":"1994","journal-title":"Somat. Cell Mol. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"s107","DOI":"10.1007\/s100720200092","article-title":"CAG mutation effect on rate of progression in Huntington\u2019s disease","volume":"23","author":"Squitieri","year":"2002","journal-title":"Neurol. Sci."},{"key":"ref_8","first-page":"65","article-title":"The biological function of the Huntingtin protein and its relevance to Huntington\u2019s Disease pathology","volume":"5","author":"Schulte","year":"2011","journal-title":"Curr. Trends Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0962-8924(00)01853-5","article-title":"Huntington\u2019s disease: The challenge for cell biologists","volume":"10","author":"Tobin","year":"2000","journal-title":"Trends Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/ng0595-67","article-title":"Comparative sequence analysis of the human and pufferfish Huntington\u2019s disease genes","volume":"10","author":"Baxendale","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/hmg\/8.9.1807","article-title":"A putative Drosophila homolog of the Huntington\u2019s disease gene","volume":"8","author":"Li","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/molbev\/msm258","article-title":"Phylogenetic Comparison of Huntingtin Homologues Reveals the Appearance of a Primitive polyQ in Sea Urchin","volume":"25","author":"Tartari","year":"2008","journal-title":"Mol. Biol. Evol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Takano, H., and Gusella, J.F. (2002). The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB\/Rel\/dorsal family transcription factor. BMC Neurosci., 3.","DOI":"10.1186\/1471-2202-3-15"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ng1503","article-title":"Polyglutamine expansion of huntingtin impairs its nuclear export","volume":"37","author":"Cornett","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature25502","article-title":"The cryo-electron microscopy structure of huntingtin","volume":"555","author":"Guo","year":"2018","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncb3101","article-title":"Huntingtin functions as a scaffold for selective macroautophagy","volume":"17","author":"Rui","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kaltenbach, L.S., Romero, E., Becklin, R.R., Chettier, R., Bell, R., Phansalkar, A., Strand, A., Torcassi, C., Savage, J., and Hurlburt, A. (2007). Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration. PLoS Genet., 3.","DOI":"10.1371\/journal.pgen.0030082"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.15252\/embj.201490808","article-title":"Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation","volume":"34","author":"Hangen","year":"2015","journal-title":"EMBO J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nguyen, G.D., Molero, A.E., Gokhan, S., and Mehler, M.F. (2013). Mark Functions of Huntingtin in Germ Layer Specification and Organogenesis. PLoS ONE, 8.","DOI":"10.1371\/annotation\/edee8dfa-6b2a-44f4-866a-098f186e27f0"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-170235","article-title":"Is Huntingtin Dispensable in the Adult Brain?","volume":"6","author":"Liu","year":"2017","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1385\/MN:28:3:259","article-title":"Wild-type huntingtin plays a role in brain development and neuronal survival","volume":"28","author":"Reiner","year":"2003","journal-title":"Mol. Neurobiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The Biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10720","DOI":"10.1523\/JNEUROSCI.2126-08.2008","article-title":"Huntingtin Modulates Transcription, Occupies Gene Promoters In Vivo, and Binds Directly to DNA in a Polyglutamine-Dependent Manner","volume":"28","author":"Benn","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington\u2019s disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1074\/jbc.M509806200","article-title":"Interaction of Huntingtin-associated Protein-1 with Kinesin Light Chain","volume":"281","author":"McGuire","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/00001756-199707070-00031","article-title":"Fast transport and retrograde movement of huntingtin and HAP 1 in axons","volume":"8","author":"Chase","year":"1997","journal-title":"Neuroreport"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1073\/pnas.0610628104","article-title":"Huntingtin facilitates dynein\/dynactin-mediated vesicle transport","volume":"104","author":"Caviston","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"689332","DOI":"10.3389\/fncel.2021.689332","article-title":"Huntingtin and the Synapse","volume":"15","author":"Barron","year":"2021","journal-title":"Front. Cell Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/hmg\/ddg156","article-title":"Huntingtin contains a highly conserved nuclear export signal","volume":"12","author":"Xia","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"24713","DOI":"10.1074\/jbc.M103501200","article-title":"Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95","volume":"276","author":"Sun","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14545","DOI":"10.1074\/jbc.C100044200","article-title":"Huntingtin\u2019s Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing","volume":"276","author":"Rigamonti","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1038\/sj.emboj.7601445","article-title":"Huntingtin inhibits caspase-3 activation","volume":"25","author":"Zhang","year":"2006","journal-title":"EMBO J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1242\/jcs.050013","article-title":"Huntingtin promotes cell survival by preventing Pak2 cleavage","volume":"122","author":"Luo","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14794","DOI":"10.1523\/JNEUROSCI.2774-11.2011","article-title":"Spatial and Temporal Requirements for huntingtin (Htt) in Neuronal Migration and Survival during Brain Development","volume":"31","author":"Tong","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Taran, A.S., Shuvalova, L.D., Lagarkova, M.A., and Alieva, I.B. (2020). Huntington\u2019s Disease\u2014An Outlook on the Interplay of the HTT Protein, Microtubules and Actin Cytoskeletal Components. Cells, 9.","DOI":"10.3390\/cells9061514"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.stemcr.2014.02.011","article-title":"Huntingtin Regulates Mammary Stem Cell Division and Differentiation","volume":"2","author":"Elias","year":"2014","journal-title":"Stem Cell Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.neuron.2010.06.027","article-title":"Huntingtin Is Required for Mitotic Spindle Orientation and Mammalian Neurogenesis","volume":"67","author":"Godin","year":"2010","journal-title":"Neuron"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.nbd.2005.11.012","article-title":"Lysosomal proteases are involved in generation of N-terminal huntingtin fragments","volume":"22","author":"Kim","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"20211","DOI":"10.1074\/jbc.M401267200","article-title":"Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity","volume":"279","author":"Gafni","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0014-4886(03)00132-8","article-title":"Huntingtin is degraded to small fragments by calpain after ischemic injury","volume":"183","author":"Kim","year":"2003","journal-title":"Exp. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12784","DOI":"10.1073\/pnas.221451398","article-title":"Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington\u2019s disease brains, associate with membranes, and undergo calpain-dependent proteolysis","volume":"98","author":"Kim","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1097-2765(02)00602-0","article-title":"Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions","volume":"10","author":"Lunkes","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/hmg\/ddn139","article-title":"Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus","volume":"17","author":"Warby","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuron.2010.06.021","article-title":"Matrix Metalloproteinases Are Modifiers of Huntingtin Proteolysis and Toxicity in Huntington\u2019s Disease","volume":"67","author":"Miller","year":"2010","journal-title":"Neuron"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/BTT.S270657","article-title":"Emerging Therapies for Huntington\u2019s Disease-Focus on N-Terminal Huntingtin and Huntingtin Exon 1","volume":"16","author":"Evers","year":"2022","journal-title":"Biol. Targets Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Tong, H., Yang, T., Liu, L., Li, C., Sun, Y., Jia, Q., Qin, Y., Chen, L., Zhao, X., and Zhou, G. (2023). Aberrant splicing of mutant huntingtin in Huntington\u2019s disease knock-in pigs. Neurobiol. Dis., 187.","DOI":"10.1016\/j.nbd.2023.106291"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nbd.2011.12.032","article-title":"Induced pluripotent stem cell lines from Huntington\u2019s disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway","volume":"46","author":"Castiglioni","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/hmg\/ddn175","article-title":"Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington\u2019s disease","volume":"17","author":"Wang","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.stem.2012.04.027","article-title":"Induced Pluripotent Stem Cells from Patients with Huntington\u2019s Disease Show CAG-Repeat-Expansion-Associated Phenotypes","volume":"11","author":"Consortium","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/nat.2013.0452","article-title":"Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification","volume":"24","author":"Evers","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"21807","DOI":"10.1074\/jbc.M109.084434","article-title":"Tracking Mutant Huntingtin Aggregation Kinetics in Cells Reveals Three Major Populations That Include an Invariant Oligomer Pool","volume":"285","author":"Olshina","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jmb.2018.03.017","article-title":"Self-assembly of Mutant Huntingtin Exon-1 Fragments into Large Complex Fibrillar Structures Involves Nucleated Branching","volume":"430","author":"Wagner","year":"2018","journal-title":"J. Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1074\/jbc.M109.093708","article-title":"Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Manner in Vitro and in Vivo","volume":"285","author":"Legleiter","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1471-4159.2005.03348.x","article-title":"Purification of neuronal inclusions of patients with Huntington\u2019s disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers","volume":"95","author":"Hoffner","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.str.2009.08.002","article-title":"Secondary structure of Huntingtin amino-terminal region","volume":"17","author":"Kim","year":"2009","journal-title":"Structure"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.molcel.2016.07.022","article-title":"Soluble Oligomers of PolyQ-Expanded Huntingtin Target a Multiplicity of Key Cellular Factors","volume":"63","author":"Kim","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0896-6273(00)80405-5","article-title":"Intranuclear Neuronal Inclusions: A Common Pathogenic Mechanism for Glutamine-Repeat Neurodegenerative Diseases?","volume":"19","author":"Ross","year":"1998","journal-title":"Neuron"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(97)08360-8","article-title":"Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?","volume":"351","author":"Davies","year":"1998","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00018-023-04882-w","article-title":"Soluble mutant huntingtin drives early human pathogenesis in Huntington\u2019s disease","volume":"80","author":"Miguez","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lajoie, P., and Snapp, E.L. (2010). Formation and Toxicity of Soluble Polyglutamine Oligomers in Living Cells. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015245"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15581","DOI":"10.1074\/jbc.RA118.002933","article-title":"Heat shock promotes inclusion body formation of mutant huntingtin (mHtt) and alleviates mHtt-induced transcription factor dysfunction","volume":"293","author":"Chen","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/hmg\/ddi064","article-title":"Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation","volume":"14","author":"Bowman","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neulet.2011.08.043","article-title":"Protective role of the ubiquitin binding protein Tollip against the toxicity of polyglutamine-expansion proteins","volume":"503","author":"Oguro","year":"2011","journal-title":"Neurosci. Lett."},{"key":"ref_67","first-page":"805","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Montserrat","year":"2016","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.sbi.2016.10.016","article-title":"Protein-protein interactions: Scoring schemes and binding affinity","volume":"44","author":"Gromiha","year":"2017","journal-title":"Curr. Opin. Struc. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"(2018). Ylva; Ivarsson; Per; Jemth Affinity and specificity of motif-based protein-protein interactions. Curr. Opin. Struc. Biol., 54, 26\u201333.","DOI":"10.1016\/j.sbi.2018.09.009"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3233\/JHD-220538","article-title":"Mutant Huntingtin Protein Interaction Map Implicates Dysregulation of Multiple Cellular Pathways in Neurodegeneration of Huntington\u2019s Disease","volume":"11","author":"Podvin","year":"2022","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1038\/s41598-018-27900-5","article-title":"Comparative Analysis of Mutant Huntingtin Binding Partners in Yeast Species","volume":"8","author":"Zhao","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cels.2022.01.005","article-title":"Dynamics of huntingtin protein interactions in the striatum identifies candidate modifiers of Huntington disease","volume":"13","author":"Greco","year":"2022","journal-title":"Cell Syst."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuron.2012.05.024","article-title":"Network Organization of the Huntingtin Proteomic Interactome in Mammalian Brain","volume":"75","author":"Shirasaki","year":"2012","journal-title":"Neuron"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"McAdam, R.L., Morton, A., Gordon, S.L., Alterman, J.F., Khvorova, A., Cousin, M.A., and Smillie, K.J. (2020). Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the httQ140\/Q140 mouse model of Huntington\u2019s disease. Neurobiol. Dis., 134.","DOI":"10.1016\/j.nbd.2019.104637"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9932","DOI":"10.1523\/JNEUROSCI.3355-05.2005","article-title":"Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington\u2019s Disease","volume":"25","author":"Valenza","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/hmg\/ddm170","article-title":"Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation","volume":"16","author":"Valenza","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.nbd.2007.07.004","article-title":"Progressive dysfunction of the cholesterol biosynthesis pathway in the R6\/2 mouse model of Huntington\u2019s disease","volume":"28","author":"Valenza","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nbd.2016.11.013","article-title":"Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington\u2019s disease: A cross-validation study in Q175 knock-in mice","volume":"98","author":"Shankaran","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/hmg\/ddz298","article-title":"Mutant huntingtin interacts with the sterol regulatory element-binding proteins and impairs their nuclear import","volume":"29","author":"Monyror","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JHD-210476","article-title":"Identification of Full-Length Wild-Type and Mutant Huntingtin Interacting Proteins by Crosslinking Immunoprecipitation in Mice Brain Cortex","volume":"10","author":"Sap","year":"2021","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.drudis.2014.03.016","article-title":"Transcriptional dysregulation in Huntington\u2019s disease: A failure of adaptive transcriptional homeostasis","volume":"19","author":"Kumar","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","article-title":"Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington\u2019s Disease","volume":"296","author":"Dunah","year":"2002","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/MCB.22.5.1277-1287.2002","article-title":"Interaction of Huntington disease protein with transcriptional activator Sp1","volume":"22","author":"Li","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.nbd.2009.07.014","article-title":"CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington\u2019s disease","volume":"36","author":"Choi","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e17056","DOI":"10.7554\/eLife.17056","article-title":"Real-time imaging of Huntingtin aggregates diverting target search and gene transcription","volume":"5","author":"Li","year":"2016","journal-title":"Elife"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e42988","DOI":"10.7554\/eLife.42988","article-title":"Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription","volume":"8","author":"Gao","year":"2019","journal-title":"Elife"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-319-71779-1_3","article-title":"Mitochondrial Dysfunction in Huntington\u2019s Disease","volume":"1049","author":"Carmo","year":"2018","journal-title":"Polyglutamine Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","article-title":"Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration","volume":"127","author":"Cui","year":"2006","journal-title":"Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lfs.2018.12.029","article-title":"Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies","volume":"218","author":"Elfawy","year":"2019","journal-title":"Life Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1523\/JNEUROSCI.20-19-07268.2000","article-title":"Huntingtin Expression Stimulates Endosomal-Lysosomal Activity, Endosome Tubulation, and Autophagy","volume":"20","author":"Kegel","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41593-022-01185-4","article-title":"Age-related Huntington\u2019s disease progression modeled in directly reprogrammed patient-derived striatal neurons highlights impaired autophagy","volume":"25","author":"Oh","year":"2022","journal-title":"Nat. Neurosci."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Long, J., Luo, X., Fang, D., Song, H., Fang, W., Shan, H., Liu, P., Lu, B., Yin, X., and Hong, L. (2022). Discovery of an autophagy inducer J3 to lower mutant huntingtin and alleviate Huntington\u2019s disease-related phenotype. Cell Biosci., 12.","DOI":"10.1186\/s13578-022-00906-3"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1083\/jcb.200504035","article-title":"Lithium induces autophagy by inhibiting inositol monophosphatase","volume":"170","author":"Sarkar","year":"2005","journal-title":"J. Cell Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1074\/jbc.M609532200","article-title":"Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and \u03b1-Synuclein","volume":"282","author":"Sarkar","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/jnc.12647","article-title":"Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington\u2019s disease","volume":"129","author":"Liu","year":"2014","journal-title":"J. Neurochem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","article-title":"Impairment of the Ubiquitin-Proteasome System by Protein Aggregation","volume":"292","author":"Bence","year":"2001","journal-title":"Science"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nbd.2010.11.018","article-title":"Proteasomal dysfunction in aging and Huntington disease","volume":"43","author":"Li","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1083\/jcb.200709080","article-title":"Impaired ubiquitin\u2013proteasome system activity in the synapses of Huntington\u2019s disease mice","volume":"180","author":"Wang","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1126\/science.1067122","article-title":"Toxic Proteins in Neurodegenerative Disease","volume":"296","author":"Taylor","year":"2002","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.molcel.2004.12.021","article-title":"Global Impairment of the Ubiquitin-Proteasome System by Nuclear or Cytoplasmic Protein Aggregates Precedes Inclusion Body Formation","volume":"17","author":"Bennett","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1523\/JNEUROSCI.2491-09.2009","article-title":"Interaction of Postsynaptic Density Protein-95 with NMDA Receptors Influences Excitotoxicity in the Yeast Artificial Chromosome Mouse Model of Huntington\u2019s Disease","volume":"29","author":"Fan","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.nbd.2011.12.019","article-title":"P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease","volume":"45","author":"Fan","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1093\/hmg\/dds154","article-title":"Calpain and STriatal-Enriched protein tyrosine Phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington\u2019s disease mouse model","volume":"21","author":"Gladding","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1038\/s41467-018-05320-3","article-title":"The ubiquitin ligase UBR5 suppresses proteostasis collapse in pluripotent stem cells from Huntington\u2019s disease patients","volume":"9","author":"Koyuncu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"102976","DOI":"10.1016\/j.scr.2022.102976","article-title":"Generation of induced pluripotent stem cells from three individuals with Huntington\u2019s disease","volume":"65","author":"Miller","year":"2022","journal-title":"Stem Cell Res."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Tom\u00e9, S., Manley, K., Simard, J.P., Clark, G.W., Slean, M.M., Swami, M., Shelbourne, P.F., Tillier, E.R.M., Monckton, D.G., and Messer, A. (2013). MSH3 Polymorphisms and Protein Levels Affect CAG Repeat Instability in Huntington\u2019s Disease Mice. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003280"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1474-4422(20)30343-4","article-title":"Interrupting sequence variants and age of onset in Huntington\u2019s disease: Clinical implications and emerging therapies","volume":"19","author":"Wright","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ajhg.2020.05.012","article-title":"Genetic and Functional Analyses Point to FAN1 as the Source of Multiple Huntington Disease Modifier Effects","volume":"107","author":"Kim","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/brain\/awz115","article-title":"MSH3 modifies somatic instability and disease severity in Huntington\u2019s and myotonic dystrophy type 1","volume":"142","author":"Michael","year":"2019","journal-title":"Brain"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Frank, S. (2009). Tetrabenazine as anti-chorea therapy in Huntington Disease: An open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. BMC Neurol., 9.","DOI":"10.1186\/1471-2377-9-62"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease","volume":"316","author":"Frank","year":"2016","journal-title":"JAMA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","article-title":"Improvement of Huntington\u2019s disease with olanzapine and valproate","volume":"343","author":"Grove","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","article-title":"Riluzole therapy in Huntington\u2019s disease (HD)","volume":"14","author":"Rosas","year":"1999","journal-title":"Mov. Disord."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Bhat, A.A., Gupta, G., Afzal, O., Kazmi, I., Al-Abbasi, F.A., Alfawaz Altamimi, A.S., Almalki, W.H., Alzarea, S.I., Singh, S.K., and Dua, K. (2023). Neuropharmacological effect of risperidone: From chemistry to medicine. Chem.-Biol. Interact., 369.","DOI":"10.1016\/j.cbi.2022.110296"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/01.WNL.0000068165.07883.64","article-title":"IV amantadine improves chorea in Huntington\u2019s disease: An acute randomized, controlled study","volume":"60","author":"Lucetti","year":"2003","journal-title":"Neurology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","article-title":"Effects of rivastigmine on motor and cognitive impairment in Huntington\u2019s disease","volume":"19","author":"Specchio","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.870120319","article-title":"Controlled Trial of Fluoxetine in Nondepressed Patients with Huntington\u2019s Disease","volume":"12","author":"Como","year":"1997","journal-title":"Mov. Disord."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2217\/pgs-2022-0161","article-title":"Use of pharmacogenetics for benzodiazepine prescription: State of the art and expectations","volume":"23","author":"Zubiaur","year":"2022","journal-title":"Pharmacogenomics"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1523\/JNEUROSCI.0782-21.2022","article-title":"Dysregulation of the Basal Ganglia Indirect Pathway in Early SymptomaticQ175 Huntington\u2019s Disease Mice","volume":"42","author":"Callahan","year":"2022","journal-title":"J. Neurosci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"11795735221092517","DOI":"10.1177\/11795735221092517","article-title":"Current and Possible Future Therapeutic Options for Huntington\u2019s Disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J. Clin. Mov. Disord."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1523\/JNEUROSCI.5473-08.2009","article-title":"Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease","volume":"29","author":"Graham","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fnsyn.2019.00003","article-title":"Altered Regulation of Striatal Neuronal N-Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model","volume":"11","author":"Kang","year":"2019","journal-title":"Front. Synaptic Neurosci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13256-023-04161-z","article-title":"Memantine administration prevented chorea movement in Huntington\u2019s disease: A case report","volume":"17","author":"Saigoh","year":"2023","journal-title":"J. Med. Case Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/mdc3.13763","article-title":"Memantine Use and Cognitive Decline in Huntington\u2019s Disease: AnEnroll-HD Study","volume":"10","author":"Ogilvie","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"893422","DOI":"10.3389\/fphar.2022.893422","article-title":"Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?","volume":"13","author":"Budgett","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuint.2019.03.020","article-title":"Metabotropic glutamate receptor 5 ablation accelerates age-related neurodegeneration and neuroinflammation","volume":"126","author":"Carvalho","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"n6387","DOI":"10.1126\/scisignal.aan6387","article-title":"mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington\u2019s disease","volume":"10","author":"Hamilton","year":"2017","journal-title":"Sci. Signal."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","article-title":"AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study","volume":"28","author":"Stocchi","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1021\/acsmedchemlett.3c00415","article-title":"Highly Potent Peptide Therapeutics to Prevent Protein Aggregation in Huntington\u2019s Disease","volume":"14","author":"Khan","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/mt.2015.157","article-title":"Inhibition of Aggregation of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington\u2019s Disease","volume":"23","author":"Chaudhary","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13023-016-0405-3","article-title":"The P42 peptide and Peptide-based therapies for Huntington\u2019s disease","volume":"11","author":"Marelli","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng864","article-title":"A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila","volume":"30","author":"Thompson","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2008.06.015","article-title":"Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice","volume":"449","author":"Popiel","year":"2009","journal-title":"Neurosci. Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/hmg\/ddm301","article-title":"HYPK, a Huntingtin interacting protein, reduces aggregates and apoptosis induced by N-terminal Huntingtin with 40 glutamines in Neuro2a cells and exhibits chaperone-like activity","volume":"17","author":"Raychaudhuri","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2014.11.035","article-title":"Chaperone protein HYPK interacts with the first 17 amino acid region of Huntingtin and modulates mutant HTT-mediated aggregation and cytotoxicity","volume":"456","author":"Choudhury","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_141","first-page":"202002283","article-title":"Loss of Hap1 selectively promotes striatal degeneration in Huntington disease mice","volume":"117","author":"Liu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3389\/fncel.2018.00381","article-title":"Huntingtin-Associated Protein 1A Regulates Store-Operated Calcium Entry in Medium Spiny Neurons from Transgenic YAC128 Mice, a Model of Huntington\u2019s Disease","volume":"12","author":"Czeredys","year":"2018","journal-title":"Front. Cell Neurosci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1523\/JNEUROSCI.23-17-06956.2003","article-title":"Lack of Huntingtin-Associated Protein-1 Causes Neuronal Death Resembling Hypothalamic Degeneration in Huntington\u2019s Disease","volume":"23","author":"Li","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1523\/JNEUROSCI.1870-13.2014","article-title":"The Regulation of Autophagosome Dynamics by Huntingtin and HAP1 Is Disrupted by Expression of Mutant Huntingtin, Leading to Defective Cargo Degradation","volume":"34","author":"Wong","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.celrep.2018.07.017","article-title":"Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation","volume":"24","author":"Pircs","year":"2018","journal-title":"Cell Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1091\/mbc.e08-07-0726","article-title":"Mutant huntingtin impairs post-Golgi trafficking to lysosomes by delocalizing optineurin\/Rab8 complex from the Golgi apparatus","volume":"20","author":"Alberch","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nbd.2018.08.010","article-title":"A role for autophagy in Huntington\u2019s disease","volume":"122","author":"Croce","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncb3125","article-title":"Huntingtin facilitates selective autophagy","volume":"17","author":"Gelman","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.jmb.2019.12.035","article-title":"Autophagy Induction as a Therapeutic Strategy for Neurodegenerative Diseases","volume":"432","author":"Djajadikerta","year":"2020","journal-title":"J. Mol. Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"107812","DOI":"10.1016\/j.neuropharm.2019.107812","article-title":"Brain-penetrant PQR620 mTOR and PQR530 PI3K\/mTOR inhibitor reduce huntingtin levels in cell models of HD","volume":"162","author":"Singer","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-021-00428-5","article-title":"Mammalian\/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration","volume":"16","author":"Querfurth","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1223911","DOI":"10.3389\/fnagi.2023.1223911","article-title":"Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in Drosophila","volume":"15","author":"Roth","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"111670","DOI":"10.1016\/j.mad.2022.111670","article-title":"Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder","volume":"204","author":"Herrero","year":"2022","journal-title":"Mech. Ageing Dev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0264-9","article-title":"Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease","volume":"51","author":"Sanchis","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuropharm.2016.04.041","article-title":"Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro","volume":"108","author":"Walter","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/JHD-160211","article-title":"Autophagy Activation by Transcription Factor EB (TFEB) in Striatum of HDQ175\/Q7 Mice","volume":"5","author":"Vodicka","year":"2016","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.neuron.2014.12.019","article-title":"Reinstating Aberrant mTORC1 Activity in Huntington\u2019s Disease Mice Improves Disease Phenotypes","volume":"85","author":"Lee","year":"2015","journal-title":"Neuron"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1083\/jcb.200507002","article-title":"p62\/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death","volume":"171","author":"Lamark","year":"2005","journal-title":"J. Cell Biol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1242\/jcs.114926","article-title":"Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates","volume":"126","author":"Korac","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.cell.2022.03.005","article-title":"CCT2 is an aggrephagy receptor for clearance of solid protein aggregates","volume":"185","author":"Ma","year":"2022","journal-title":"Cell"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1080\/15548627.2020.1760014","article-title":"Impact of differential and time-dependent autophagy activation on therapeutic efficacy in a model of Huntington disease","volume":"17","author":"Hersbach","year":"2021","journal-title":"Autophagy"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1073\/pnas.1402215111","article-title":"Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A","volume":"111","author":"Bhat","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.brainres.2016.03.027","article-title":"Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin","volume":"1643","author":"Lin","year":"2016","journal-title":"Brain Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"25108","DOI":"10.1074\/jbc.M110.187591","article-title":"Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6) Associates with Huntingtin Protein and Promotes Its Atypical Ubiquitination to Enhance Aggregate Formation","volume":"286","author":"Zucchelli","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/aps.2018.11","article-title":"Proteostasis in Huntington\u2019s disease: Disease mechanisms and therapeutic opportunities","volume":"39","author":"Harding","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2015.05.010","article-title":"The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster","volume":"82","author":"Tsou","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1038\/cddis.2012.166","article-title":"Dysregulation of core components of SCF complex in poly-glutamine disorders","volume":"3","author":"Bhutani","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2009.05.039","article-title":"Effects of partial suppression of parkin on huntingtin mutant R6\/1 mice","volume":"1281","author":"Rubio","year":"2009","journal-title":"Brain Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuroscience.2016.02.054","article-title":"Gene therapy by proteasome activator, PA28\u03b3, improves motor coordination and proteasome function in Huntington\u2019s disease YAC128 mice","volume":"324","author":"Jeon","year":"2016","journal-title":"Neuroscience"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e2114303119","DOI":"10.1073\/pnas.2114303119","article-title":"Suppression of toxicity of the mutant huntingtin protein by its interacting compound, desonide","volume":"119","author":"Song","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.071058398","article-title":"Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington\u2019s disease","volume":"98","author":"Lecerf","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Denis, H.L., David, L.S., and Cicchetti, F. (2019). Antibody-based therapies for Huntington\u2019s disease: Current status and future directions. Neurobiol. Dis., 132.","DOI":"10.1016\/j.nbd.2019.104569"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.022631799","article-title":"Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity","volume":"99","author":"Khoshnan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","article-title":"Intrabodies Binding the Proline-Rich Domains of Mutant Huntingtin Increase Its Turnover and Reduce Neurotoxicity","volume":"28","author":"Southwell","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Butler, D.C., and Messer, A. (2011). Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0029199"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"36631","DOI":"10.1038\/srep36631","article-title":"A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses","volume":"6","author":"Zha","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","article-title":"Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin","volume":"181","author":"Wang","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e2301120","DOI":"10.1002\/advs.202301120","article-title":"A Specific Mini-Intrabody Mediates Lysosome Degradation of Mutant Huntingtin","volume":"10","author":"Li","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/exnr.1999.7170","article-title":"Increased complement biosynthesis by microglia and complement activation on neurons in Huntington\u2019s disease","volume":"159","author":"Singhrao","year":"1999","journal-title":"Exp. Neurol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12017-009-8085-y","article-title":"The role of the complement system and the activation fragment C5a in the central nervous system","volume":"12","author":"Woodruff","year":"2010","journal-title":"Neuromol. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1038\/s41591-023-02566-3","article-title":"Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington\u2019s disease","volume":"29","author":"Wilton","year":"2023","journal-title":"Nat. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41583-022-00641-1","article-title":"Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders","volume":"24","author":"Brandebura","year":"2023","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41419-018-0599-5","article-title":"Sphingosine kinase 1-associated autophagy differs between neurons and astrocytes","volume":"9","author":"Uzor","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/brain\/awac068","article-title":"Reactive astrocytes promote proteostasis in Huntington\u2019s disease through the JAK2-STAT3 pathway","volume":"146","author":"Abjean","year":"2023","journal-title":"Brain"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/brain\/awab186","article-title":"SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington\u2019s disease phenotypes","volume":"144","author":"Birolini","year":"2021","journal-title":"Brain"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1523\/JNEUROSCI.3693-15.2016","article-title":"Dysfunctional Calcium and Glutamate Signaling in Striatal Astrocytes from Huntington\u2019s Disease Model Mice","volume":"36","author":"Jiang","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1093\/nar\/gkab152","article-title":"Somatic CAG expansion in Huntington\u2019s disease is dependent on the MLH3 endonuclease domain, which can be excluded via splice redirection","volume":"49","author":"Roy","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_188","first-page":"650","article-title":"FAN1 modifies Huntington\u2019s disease progression by stabilising the expanded HTT CAG repeat","volume":"28","author":"Robert","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"109649","DOI":"10.1016\/j.celrep.2021.109649","article-title":"FAN1 controls mismatch repair complex assembly via MLH1 retention to stabilize CAG repeat expansion in Huntington\u2019s disease","volume":"36","author":"Goold","year":"2021","journal-title":"Cell Rep."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ymthe.2023.05.006","article-title":"Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington\u2019s disease","volume":"31","author":"Belgrad","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Bai, D., Zhu, L., Jia, Q., Duan, X., Chen, L., Wang, X., Hou, J., Jiang, G., Yang, S., and Li, S. (2023). Loss of TDP-43 promotes somatic CAG repeat expansion in Huntington\u2019s disease knock-in mice. Prog. Neurobiol., 227.","DOI":"10.1016\/j.pneurobio.2023.102484"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41598-024-52667-3","article-title":"Dose-dependent reduction of somatic expansions but not Htt aggregates by di-valent siRNA-mediated silencing of MSH3 in HdhQ111 mice","volume":"14","author":"Driscoll","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"18736","DOI":"10.1038\/srep18736","article-title":"Curcumin modulates cell death and is protective in Huntington\u2019s disease model","volume":"6","author":"Chongtham","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13195-021-00843-2","article-title":"A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer\u2019s disease","volume":"13","author":"Prins","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"626755","DOI":"10.3389\/fimmu.2021.626755","article-title":"MSCs and Inflammatory Cells Crosstalk in Regenerative Medicine: Concerted Actions for Optimized Resolution Driven by Energy Metabolism","volume":"12","author":"Varin","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/157488811795495486","article-title":"Mesenchymal stem cells neuronal differentiation ability: A real perspective for nervous system repair?","volume":"6","author":"Scuteri","year":"2011","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/scrt545","article-title":"Reductions in behavioral deficits and neuropathology in the R6\/2 mouse model of Huntington\u2019s disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number","volume":"6","author":"Rossignol","year":"2015","journal-title":"Stem Cell Res. Ther."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbr.2010.11.006","article-title":"Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington\u2019s disease: Morphological and behavioral outcomes","volume":"217","author":"Rossignol","year":"2011","journal-title":"Behav. Brain Res."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Im, W., Lee, S.T., Park, J.E., Oh, H.J., and Kim, M. (2010). Transplantation of patient-derived adipose stem cells in YAC128 Huntington\u2019s disease transgenic mice. PLoS Curr., 2.","DOI":"10.1371\/currents.RRN1183"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Karaka\u015f, N., Bay, S., T\u00fcrkel, N., \u00d6ztun\u00e7, N., \u00d6nc\u00fcl, M., Bilgen, H., Shah, K., \u015eahin, F., and \u00d6zt\u00fcrk, G. (2020). Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. PLoS ONE, 15.","DOI":"10.1101\/2020.01.20.912394"},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Wang, J., Hao, R., Jiang, T., Guo, X., Zhou, F., Cao, L., Gao, F., Wang, G., Wang, J., and Ning, K. (2022). Rebuilding hippocampus neural circuit with hADSC-derived neuron cells for treating ischemic stroke. Cell Biosci., 12.","DOI":"10.1186\/s13578-022-00774-x"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Kaminska, A., Radoszkiewicz, K., Rybkowska, P., Wedzinska, A., and Sarnowska, A. (2022). Interaction of Neural Stem Cells (NSCs) and Mesenchymal Stem Cells (MSCs) as a Promising Approach in Brain Study and Nerve Regeneration. Cells, 11.","DOI":"10.3390\/cells11091464"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1582-4934.2008.00657.x","article-title":"Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation","volume":"13","author":"Rossignol","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neulet.2007.05.066","article-title":"Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions","volume":"423","author":"Song","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","article-title":"Motor and cognitive improvements in patients with Huntington\u2019s disease after neural transplantation","volume":"356","author":"Nguyen","year":"2000","journal-title":"Lancet"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/mds.28201","article-title":"Human Fetal Cell Therapy in Huntington\u2019s Disease: A Randomized, Multicenter, PhaseII Trial","volume":"35","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jnnp.73.6.678","article-title":"Unilateral transplantation of human primary fetal tissue in four patients with Huntington\u2019s disease: NEST-UK safety report ISRCTN no 36485475","volume":"73","author":"Rosser","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41420-023-01532-9","article-title":"Directional induction of neural stem cells, a new therapy for neurodegenerative diseases and ischemic stroke","volume":"9","author":"Nie","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/stem.3191","article-title":"Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington\u2019s disease","volume":"38","author":"Yoon","year":"2020","journal-title":"Stem Cells"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1016\/j.ymthe.2023.10.003","article-title":"Transplanted human neural stem cells rescue phenotypes in zQ175 Huntington\u2019s disease mice and innervate the striatum","volume":"31","author":"Holley","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"620","DOI":"10.5966\/sctm.2013-0151","article-title":"Intrastriatal Transplantation of Adenovirus-Generated Induced Pluripotent Stem Cells for Treating Neuropathological and Functional Deficits in a Rodent Model of Huntington\u2019s Disease","volume":"3","author":"Fink","year":"2014","journal-title":"Stem Cell Transl. Med."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Csobonyeiova, M., Polak, S., and Danisovic, L. (2020). Recent Overview of the Use of iPSCs Huntington\u2019s Disease Modeling and Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062239"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3389\/fnins.2017.00628","article-title":"Induced Pluripotent Stem Cell-Derived Neural Stem Cell Transplantations Reduced Behavioral Deficits and Ameliorated Neuropathological Changes in YAC128 Mouse Model of Huntington\u2019s Disease","volume":"11","author":"Culver","year":"2017","journal-title":"Front. Neurosci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tins.2023.02.005","article-title":"The potential of gene editing for Huntington\u2019s disease","volume":"46","author":"Duan","year":"2023","journal-title":"Trends Neurosci."},{"key":"ref_217","first-page":"4566","article-title":"Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","article-title":"Reversal of Phenotypic Abnormalities by CRISPR\/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells","volume":"8","author":"Xu","year":"2017","journal-title":"Stem Cell Rep."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.stemcr.2018.03.007","article-title":"hPSC-Derived Striatal Cells Generated Using a Scalable 3D Hydrogel Promote Recovery in a Huntington Disease Mouse Model","volume":"10","author":"Adil","year":"2018","journal-title":"Stem Cell Rep."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.25354","article-title":"Outcome of cell suspension allografts in a patient with Huntington\u2019s disease","volume":"84","author":"Maxan","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00401-016-1582-9","article-title":"Human-to-mouse prion-like propagation of mutant huntingtin protein","volume":"132","author":"Jeon","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic Silencing of Mutant Huntingtin With siRNA Attenuates Striatal and Cortical Neuropathology and Behavioral Deficits","volume":"104","author":"Difiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2012.08.012","article-title":"Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression","volume":"163","author":"Burgess","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/mt.2016.126","article-title":"Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing","volume":"24","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/brain\/awab354","article-title":"Therapeutic reversal of Huntington\u2019s disease by in vivo self-assembled siRNAs","volume":"144","author":"Li","year":"2021","journal-title":"Brain"},{"key":"ref_227","first-page":"36","article-title":"Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease","volume":"48","author":"Caron","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtn.2022.04.031","article-title":"A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington\u2019s disease","volume":"28","author":"Przybyl","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"eabb8920","DOI":"10.1126\/scitranslmed.abb8920","article-title":"Widespread and sustained target engagement in Huntington\u2019s disease minipigs upon intrastriatal microRNA-based gene therapy","volume":"13","author":"Evers","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington\u2019s Disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Tung, C., Huang, P., Chan, S.C., Cheng, P., and Yang, S. (2021). The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington\u2019s disease. J. Biomed. Sci., 28.","DOI":"10.1186\/s12929-021-00755-1"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington\u2019s disease therapy:siRNA versus shRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.omtn.2019.12.012","article-title":"Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression","volume":"19","author":"Ostrovska","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Drouet, V., Ruiz, M., Zala, D., Feyeux, M., Auregan, G., Cambon, K., Troquier, L., Carpentier, J., Aubert, S., and Merienne, N. (2014). Allele-Specific Silencing of Mutant Huntingtin in Rodent Brain and Human Stem Cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099341"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2008.50","article-title":"AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease","volume":"16","author":"Franich","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000517686","article-title":"Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders","volume":"43","author":"Hill","year":"2021","journal-title":"Dev. Neurosci."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10571-020-00919-x","article-title":"Direct Administration and Gene Modulation Using Antisense Oligonucleotides within the CNS","volume":"41","author":"Wahlestedt","year":"2021","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/nat.2018.0775","article-title":"Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington\u2019s Disease","volume":"29","author":"Imbert","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained Therapeutic Reversal of Huntington\u2019s Disease by Transient Repression of Huntingtin Synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jconrel.2023.07.027","article-title":"Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks","volume":"360","author":"Aly","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Mendon\u00e7a, M.C.P., Sun, Y., Cronin, M.F., Lindsay, A.J., Cryan, J.F., and O Driscoll, C.M. (2023). Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020520"},{"key":"ref_243","first-page":"3","article-title":"The effects of huntingtin-lowering: What do we know so far?","volume":"9","author":"Kaemmerer","year":"2019","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"r3959","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JHD-229003","article-title":"Perspective: Tominersen Testing Finds a Way Forward","volume":"11","author":"Aronin","year":"2022","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington\u2019s Disease Mouse Model","volume":"17","author":"Ekman","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Kolli, N., Lu, M., Maiti, P., Rossignol, J., and Dunbar, G.L. (2017). CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington\u2019s Disease. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040754"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-biochem-010909-095056","article-title":"The Discovery of Zinc Fingers and Their Applications in Gene Regulation and Genome Manipulation","volume":"79","author":"Klug","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat. Med."},{"key":"ref_251","first-page":"18264","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Herrmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3727\/096368916X690863","article-title":"Allele-specific reduction of the mutant huntingtin allele using transcription activator-like effectors in human Huntington\u2019s disease fibroblasts","volume":"25","author":"Fink","year":"2016","journal-title":"Cell Transplant."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnins.2018.00075","article-title":"Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases","volume":"12","author":"Dabrowska","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s11033-022-08175-6","article-title":"CRISPR-Cas9 mediated genome editing of Huntington\u2019s disease neurospheres","volume":"50","author":"Han","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease","volume":"127","author":"Yang","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1093\/brain\/awab190","article-title":"Huntingtin silencing delays onset and slows progression of Huntington\u2019s disease: A biomarker study","volume":"144","author":"Hongshuai","year":"2021","journal-title":"Brain"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/hum.2020.323","article-title":"Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities","volume":"33","author":"Oikemus","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41551-023-01007-3","article-title":"Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington\u2019s disease","volume":"7","author":"Yan","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cell.2018.09.001","article-title":"Structural basis for the RNA-guided ribonuclease activity of CRISPR-Cas13d","volume":"175","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","article-title":"Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors","volume":"173","author":"Konermann","year":"2018","journal-title":"Cell"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-targeting CRISPR\u2013Cas13d system alleviates disease-related phenotypes in Huntington\u2019s disease models","volume":"26","author":"Morelli","year":"2023","journal-title":"Nat. Neurosci."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington\u2019s Disease Minipig Model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Richard","year":"2012","journal-title":"Brain"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1073\/pnas.1524575113","article-title":"Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Pla, P., Orvoen, S., Benstaali, C., Dodier, S., Gardier, A.M., David, D.J., Humbert, S., and Saudou, F. (2013). Huntingtin Acts Non Cell-Autonomously on Hippocampal Neurogenesis and Controls Anxiety-Related Behaviors in Adult Mouse. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073902"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1021592","DOI":"10.3389\/fncel.2022.1021592","article-title":"Huntingtin exon 1 deletion does not alter the subcellular distribution of huntingtin and gene transcription in mice","volume":"16","author":"Zhao","year":"2022","journal-title":"Front. Cell Neurosci."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"d344","DOI":"10.1093\/braincomms\/fcad344","article-title":"Revisiting the outcome of adult wild-type Htt inactivation in the context of HTT-lowering strategies for Huntington\u2019s disease","volume":"5","author":"Regio","year":"2023","journal-title":"Brain Commun."},{"key":"ref_268","doi-asserted-by":"crossref","unstructured":"Dietrich, P., Johnson, I.M., Alli, S., and Dragatsis, I. (2017). Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. PLoS Genet., 13.","DOI":"10.1371\/journal.pgen.1006846"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the Mouse Huntington\u2019s Disease Gene Homolog Hdh","volume":"269","author":"Duyao","year":"1995","journal-title":"Science"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"46740","DOI":"10.1038\/srep46740","article-title":"Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells","volume":"7","author":"Miller","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-4939-9139-6_10","article-title":"MRI-Guided Focused Ultrasound for Targeted Delivery of rAAV to the Brain","volume":"1950","author":"Noroozian","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"d84","DOI":"10.1093\/braincomms\/fcad084","article-title":"A PET-CT study on neuroinflammation in Huntington\u2019s disease patients participating in a randomized trial with laquinimod","volume":"5","author":"Roussakis","year":"2023","journal-title":"Brain Commun."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3233\/JHD-200440","article-title":"Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study","volume":"9","author":"Mcgarry","year":"2020","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Landwehrmeyer","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease","volume":"28","author":"Investigators","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Claassen","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/bcp.15635","article-title":"A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington\u2019s disease","volume":"89","author":"Gamez","year":"2023","journal-title":"Brit. J. Clin. Pharmacol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST-E study of creatine for Huntington disease","volume":"89","author":"Hersch","year":"2017","journal-title":"Neurology"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1212\/WNL.0000000000001214","article-title":"Triheptanoin improves brain energy metabolism in patients with Huntington disease","volume":"84","author":"Adanyeguh","year":"2015","journal-title":"Neurology"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-022-01919-8","article-title":"Pepinemab antibody blockade of SEMA4D in early Huntington\u2019s disease: A randomized, placebo-controlled, phase 2 trial","volume":"28","author":"Feigin","year":"2022","journal-title":"Nat. Med."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/ptj\/pzz075","article-title":"Physical Activity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People with Huntington Disease","volume":"99","author":"Drew","year":"2019","journal-title":"Phys. Ther."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.omtm.2019.09.010","article-title":"AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes","volume":"15","author":"Keskin","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3233\/JHD-229006","article-title":"Huntington\u2019s Disease Clinical Trials Corner: November 2022","volume":"11","author":"Tabrizi","year":"2022","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1038\/s41467-021-27157-z","article-title":"Small molecule splicing modifiers with systemic HTT-lowering activity","volume":"12","author":"Bhattacharyya","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"6797","DOI":"10.1038\/s41467-022-34419-x","article-title":"An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington\u2019s disease patient neurons","volume":"13","author":"Krach","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"11021","DOI":"10.1021\/acs.jmedchem.8b01291","article-title":"Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA)","volume":"61","author":"Cheung","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J. Cell Mol. Med."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s13311-021-01022-9","article-title":"The sigma 1 receptor mediates pridopidine rescue of mitochondria1 function in huntington disease mode1s","volume":"18","author":"Naia","year":"2021","journal-title":"Neurotherapeutics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3845\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:21:04Z","timestamp":1760106064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":289,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25073845"],"URL":"https:\/\/doi.org\/10.3390\/ijms25073845","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}